Join        Login             Stock Quote

Pfizer (PFE), Protalix (PLX) Say EC Refuses Marketing Authorization for Gaucher Disease Therapy

 November 01, 2012 11:06 AM

(By Balachander) Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics Inc. (NYSEAMEX: PLX) said the European Commission (EC) has refused the marketing authorization for taliglucerase alfa, an enzyme replacement therapy (ERT) for the treatment of Gaucher disease.

The EC has backed a recommendation from the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) not to issue a marketing authorization for taliglucerase alfa in the European Union.

"We are disappointed by the EC's decision on taliglucerase alfa and believe it is important, given the history of past shortages, for the Gaucher disease community in the EU to have a third treatment option available," said Diem Nguyen, General Manager, Pfizer Biosimilars. "We will continue to work closely with our partner, Protalix, to make taliglucerase alfa available to the Gaucher disease community in other countries."

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

The CHMP recommendation was not related to the safety, quality or efficacy of taliglucerase alfa, but solely to the specific requirements of the European Union (EU) Orphan Drug Regulation, the companies noted.

Taliglucerase alfa was approved by the U.S. Food and Drug Administration in May 2012 for the long-term enzyme replacement therapy (ERT) of adults with a confirmed diagnosis of Type 1 Gaucher disease and was approved by Israel's Ministry of Health in September 2012.

[Related -Six Stocks That Could Get An October Bump From The FDA]

In November 2009, Pfizer and Israel-based Protalix agreed to develop and commercialize taliglucerase alfa. Under the terms of the agreement, Pfizer received exclusive worldwide licensing rights for the commercialization of taliglucerase alfa, while Protalix retained the exclusive commercialization rights in Israel.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageMr. Market's Wary Outlook: Less Severe But Still Worrisome

Mr. Market’s cautious outlook of late is less acute at the moment relative to recent history, but it’s not read on...

article imageThere's One Problem With This Market Rally...

All major U.S. indices closed higher last week, logging the second week of strength following choppy read on...

article imageWill Last Week’s Relief Rally In Emerging Markets Last?

Stocks in emerging markets posted their best weekly gain in nearly four years last week. Analysts are read on...

article imageHow Much Longer Can Our Unaffordable Housing Prices Last?

Markets discover price via supply and demand: Big demand + limited supply = rising prices. Abundant supply read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.